Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis
Patent disclosure · 2018
- What the patent describes
- Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
- Reported evidence
- The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.
Wheel activity · Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900 · Desynchronized rats · Third day
Reported patent results
Reported findings
Some activity and REM-sleep measures improved relative to untreated desynchronization, while sleep timing remained abnormal.
Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
Population or model Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Wheel activity | Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900 | Desynchronized rats · Third day |
| REM-sleep duration | Reported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM threshold | Threshold: REM duration >50% of the baseline group average |
| Persisting abnormality | REM-onset latency remained approximately twice baseline; wakefulness remained elevated | Improvement versus injury did not mean normalization |
| Acute observations | No deaths or listed overt neurological/behavioral abnormalities reported | Animal observations only · 14 days |
The combination does not isolate Cyclontane, and sleep comparisons vary by experiment. Animal safety observations do not establish human safety of this combination.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Use. Later Cyclontane use claims and experimental support; neither a grant nor a comparator establishes human efficacy.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2674342C2 ↗ · 2018-12-07
- Earliest priority / filing
- 2016-11-28 / 2016-11-28
- Original applicant / assignee
- Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 62557472 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition of 1-hydroxy-4-cyclohexylaminoadamantane hydrochloride and sodium salt of 4-hydroxymic acid, improving mental and physical efficiency when having desynchronosis
Inventors: Сергей Борисович Середенин; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Любовь Николаевна Грушевская; Надежда Михайловна Зайцева; Константин Викторович Алексеев; Евгения Викторовна Блынская; Анна Сергеевна Михеева; Людмила Михайловна Гаевая; Мария Сергеевна Сергеева; Татьяна Александровна Воронина; Светлана Александровна Литвинова; Инга Геннадиевна Капица; Елена Анатольевна Иванова; Татьяна Сергеевна Калинина.
Study limitations and source details
Study limitations
- Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
- No clinical sleep benefit or safe self-use regimen follows from these experiments.
Source details
Patent
Selected source passages checked; complete methods and risk of bias not appraised.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
Author unconfirmed. Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense